Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults.
作者信息
Ornellas Tehane, Chavez Benjamin
出版信息
P T. 2011 May;36(5):255-62.
Abstract
摘要
相似文献
1
2
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).纳曲酮缓释/安非他酮缓释片治疗体重和肥胖相关风险因素的随机、3 期临床试验（COR-II）。
Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309.
3
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.纳曲酮/安非他酮用于治疗肥胖症及伴有2型糖尿病的肥胖症。
Future Cardiol. 2016 Mar;12(2):129-38. doi: 10.2217/fca.15.79. Epub 2015 Dec 18.
4
5
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?纳曲酮缓释（SR）联合安非他酮 SR 组合疗法治疗肥胖症：“新手上路”？
Ann Med. 2011 Jun;43(4):249-58. doi: 10.3109/07853890.2010.541490. Epub 2011 Jan 24.
6
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.纳曲酮联合安非他酮对超重和肥胖成年人体重减轻的影响（COR-I）：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.
7
Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review.Contrave（纳曲酮与安非他酮复方制剂）、纳曲酮、安非他酮或纳曲酮的使用与主要不良心血管事件：一项系统文献综述
Diabetes Metab Syndr Obes. 2022 Sep 29;15:3049-3067. doi: 10.2147/DMSO.S381652. eCollection 2022.
8
Acute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave).与安非他酮/纳曲酮（Contrave）相关的急性泛发性红斑脓疱型银屑病
J Emerg Med. 2017 Apr;52(4):e111-e113. doi: 10.1016/j.jemermed.2016.11.034. Epub 2017 Jan 24.
9
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.Contrave，一种安非他酮和纳曲酮的联合疗法，用于潜在治疗肥胖症。
Curr Opin Investig Drugs. 2009 Oct;10(10):1117-25.
10
ACS chemical neuroscience molecule spotlight on contrave.ACS 化学神经科学杂志特写：康百视。
ACS Chem Neurosci. 2011 Sep 21;2(9):484-6. doi: 10.1021/cn200076y.
引用本文的文献
1
Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care.纳曲酮和安非他酮固定剂量缓释复方制剂在基层医疗中作为肥胖症治疗药物的合理应用。
Obes Pillars. 2025 Feb 26;14:100170. doi: 10.1016/j.obpill.2025.100170. eCollection 2025 Jun.
2
The Evolving Role of Weight Loss Pharmacotherapy.减肥药物治疗的角色演变
Gastroenterol Hepatol (N Y). 2025 Mar;21(3):172-179.
3
Obesity management for cardiovascular disease prevention.预防心血管疾病的肥胖管理。
Obes Pillars. 2023 May 23;7:100069. doi: 10.1016/j.obpill.2023.100069. eCollection 2023 Sep.
4
Combination Therapy: A New Tool for the Management of Obesity.联合治疗：肥胖管理的新工具。
Endocr Metab Immune Disord Drug Targets. 2024;24(4):402-417. doi: 10.2174/1871530323666230825140808.
5
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats.托吡酯、安非他酮和纳曲酮单独或联合对肥胖大鼠皮下脂肪组织的影响。
Einstein (Sao Paulo). 2022 May 30;20:eAO5587. doi: 10.31744/einstein_journal/2022AO5587. eCollection 2022.
6
Combined Anti-Adipogenic Effects of Hispidulin and -Synephrine on 3T3-L1 Adipocytes.槐皮素和辛弗林联合抗 3T3-L1 脂肪细胞形成作用。
Biomolecules. 2021 Nov 25;11(12):1764. doi: 10.3390/biom11121764.
7
Melanocortin-4 receptor complexity in energy homeostasis,obesity and drug development strategies.黑素皮质素 4 受体在能量平衡、肥胖和药物开发策略中的复杂性。
Diabetes Obes Metab. 2022 Apr;24(4):583-598. doi: 10.1111/dom.14618. Epub 2022 Jan 11.
8
Cerebral μ-opioid and CB receptor systems have distinct roles in human feeding behavior.大脑 μ 阿片和 CB 受体系统在人类摄食行为中具有不同的作用。
Transl Psychiatry. 2021 Aug 27;11(1):442. doi: 10.1038/s41398-021-01559-5.
9
Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system.戒烟会增加垃圾食品的摄入：内源性阿片系统的作用。
Drug Alcohol Depend. 2021 Aug 1;225:108819. doi: 10.1016/j.drugalcdep.2021.108819. Epub 2021 Jun 18.
10
Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures.探究盐酸安非他酮和盐酸纳曲酮从不同化学结构的生物聚合物基质中的释放情况。
Polymers (Basel). 2021 Apr 30;13(9):1456. doi: 10.3390/polym13091456.
本文引用的文献
1
Indexed Pain Journals.索引疼痛期刊。
J Pain Palliat Care Pharmacother. 2008;22(1):45-46. doi: 10.1080/15360280801989377.
2
Body-mass index and mortality among 1.46 million white adults.146 万白人成年人的体重指数与死亡率。
N Engl J Med. 2010 Dec 2;363(23):2211-9. doi: 10.1056/NEJMoa1000367.
3
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.纳曲酮联合安非他酮对超重和肥胖成年人体重减轻的影响（COR-I）：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.
4
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.COR-BMOD 试验：作为行为修正辅助治疗的纳曲酮 SR/安非他酮 SR 联合疗法的减肥效果。
Obesity (Silver Spring). 2011 Jan;19(1):110-20. doi: 10.1038/oby.2010.147. Epub 2010 Jun 17.
5
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.比较联合使用安非他酮和纳曲酮治疗肥胖症与单药治疗和安慰剂的效果。
J Clin Endocrinol Metab. 2009 Dec;94(12):4898-906. doi: 10.1210/jc.2009-1350. Epub 2009 Oct 21.
Zotero 插件